BREAKING: The FDA has authorized booster doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines for everyone 18 and older who is already considered fully vaccinated.
The U.S. Food and Drug Administration on Friday authorized booster doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines for everyone 18 and older who is already considered fully vaccinated, teeing up many Americans to gain extra protection ahead of a possible winter surge in cases.
Currently, only those 65 and older and people who are at high-risk of contracting the virus, either because of their job, where they live, or underlying conditions, are eligible for Pfizer-BioNTech and Moderna boosters six months after their second shot. Everyone 18 and older who received Johnson & Johnson's one-dose COVID-19 vaccine is eligible for a booster two months after getting their initial shot.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA Could Authorize Moderna Booster Shots for All Adults This WeekThe FDA could authorize booster shots of Moderna’s COVID-19 vaccine for all adults as early as this week.
Weiterlesen »
FDA to Authorize Pfizer Booster Shots for All Adults This WeekThe FDA intends to authorize booster shots of the Pfizer-BioNTech COVID-19 vaccine for all adults this week — potentially as early as Thursday.
Weiterlesen »
BMO initiates Pfizer at outperform, says Covid drugs and strong pipeline will boost pharma stockNew for subscribers: BMO initiates Pfizer at outperform, says Covid drugs and strong pipeline will boost pharma stock. Check out CNBCPro today.
Weiterlesen »
Plaintiffs' lawyers get $115 mln in fees in Pfizer EpiPen dealA federal judge on Wednesday signed off on Pfizer Inc's $345 million settlement resolving claims by consumers who say they overpaid for the emergency allergy treatment EpiPen, and awarded plaintiffs' firms including Robbins Geller Rudman & Dowd and Keller Rohrback $115 million in fees.
Weiterlesen »